Prana Capital Management LP purchased a new position in shares of Centene Co. (NYSE:CNC – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,160 shares of the company’s stock, valued at approximately $555,000.
Several other large investors have also recently made changes to their positions in the business. Norges Bank bought a new position in shares of Centene in the fourth quarter worth approximately $1,536,167,000. AQR Capital Management LLC grew its holdings in shares of Centene by 42.8% in the fourth quarter. AQR Capital Management LLC now owns 7,742,698 shares of the company’s stock worth $469,053,000 after purchasing an additional 2,319,952 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Centene by 21.7% in the fourth quarter. Invesco Ltd. now owns 10,555,456 shares of the company’s stock worth $639,450,000 after purchasing an additional 1,884,358 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Centene by 91.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,770,426 shares of the company’s stock worth $228,414,000 after purchasing an additional 1,802,265 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in shares of Centene by 32.3% in the fourth quarter. Ameriprise Financial Inc. now owns 6,469,062 shares of the company’s stock worth $391,854,000 after purchasing an additional 1,578,917 shares during the last quarter. 93.63% of the stock is owned by hedge funds and other institutional investors.
Centene Price Performance
CNC opened at $59.56 on Thursday. The stock has a 50-day moving average price of $60.58 and a 200-day moving average price of $60.47. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.11 and a quick ratio of 1.10. The firm has a market cap of $29.64 billion, a PE ratio of 9.54, a P/E/G ratio of 0.80 and a beta of 0.48. Centene Co. has a 1 year low of $55.03 and a 1 year high of $80.59.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Wells Fargo & Company dropped their price target on Centene from $76.00 to $72.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Guggenheim reaffirmed a “neutral” rating on shares of Centene in a research note on Tuesday, April 29th. Jefferies Financial Group dropped their price target on Centene from $64.00 to $61.00 and set a “hold” rating for the company in a research note on Tuesday, April 29th. StockNews.com lowered Centene from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 28th. Finally, Argus lowered Centene from a “buy” rating to a “hold” rating in a research note on Thursday, February 6th. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.77.
Check Out Our Latest Analysis on CNC
About Centene
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Featured Articles
- Five stocks we like better than Centene
- How to Plot Fibonacci Price Inflection Levels
- Homebuilders: Oversold, Undervalued, and Ready to Run?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- AMD’s AI-Powered Stock Price Rally Just Shifted Gears
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.